A target in the development of treatments that control autophagy, in cell biology and human illness, and in membrane trafficking processes that rely on LC3 lipidation. Inactivating ATG7 increases the efficacy of anti-cancer medicines in the treatment of lung and breast cancer cells by attenuating its capacity to sensitize tumor cells to cancer treatments. Here, ATG7 is linked to neoplasm.